Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension

Hypertension

Volumn 37, Issue 4, 2001, Pages 1108-1113

  Quaschning, Thomas ^a,b,c   D'Uscio, Livius V ^a,b,c   Shaw, Sidney ^a,b,c   Lüscher, Thomas F ^a,b,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Captopril; Endothelium; Hypertension, sodium dependent; Nitric oxide

Indexed keywords

ACETYLCHOLINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; NEUROHORMONE; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; OMAPATRILAT; PEPTIDASE; PLACEBO; PROTEINASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SALT INTAKE; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL;

EID: 0035045775     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.37.4.1108     Document Type: Article

References (47)

1. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
3. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins
4. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin
5. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: Studies in perfused mesenteric resistance arteries
6. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans
7. The role of endothelium in human hypertension
8. Effect of angiotensin-converting enzyme inhibitors on the peripheral circulation in heart failure
9. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension
10. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II
11. Sustained antihypertensive actions of a dual angiotensin-converting-enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects
12. Vasopeptidase inhibition: A new concept in blood pressure management
13. Renal, cardiac and endocrine effects of long-term vasopeptidase inhibition in chronic heart failure
14. Omapatrilat, a vasopeptidase inhibitor, produces long-term beneficial haemodynamic and neurohormonal effects in heart failure
15. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: Role of natriuretic peptides and angiotensin II
16. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c- terminal fragment from big endothelin-1
17. Clearance of brain natriuretic peptide in patients with chronic heart failure: Indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism
18. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11
19. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones
20. Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: Influence of bradykinin
21. Effects of omapatrilat in low, normal, and high renin experimental hypertension
22. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase
23. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure
24. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs
25. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure
26. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: A potential therapeutic approach in hypertension
27. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans
28. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension
29. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus
30. Increased vasodilator responses to acetylcholine in psychosocial hypertensive mice
31. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts
32. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt- sensitive hypertension
33. Basal nitric oxide synthesis in essential hypertension
34. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
35. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation
36. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
37. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
38. Some statistical methods useful in circulation research
39. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats
40. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats
41. Antihypertensive treatment normalizes decreased endothelium- dependent relaxations in rats with salt-induced hypertension
42. Nitric oxide synthase isotype expression in salt-sensitive and salt-resistant Dahl rats
43. Release of endothelin from the porcine aorta: Inhibition by endothelium-derived nitric oxide
44. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: Role of blood pressure and endothelial function
45. Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), in healthy male subjects
46. The vasopeptidase inhibitor omapatrilat has a favorable pressure-independent effect on conduit vessel stiffness in patients with congestive heart failure
47. Vasopeptidase inhibitor or angiotensin converting enzyme inhibitor in heart failure? Results of the IMPRESS trial